Two approvals in a single Monday is a pretty good way to start the week. Roche Holdings AG (RHHBY) announced that the U.S. Food and Drug Administration cleared two treatments across its breast cancer and immunology portfolios: Wilserdly for advanced breast cancer and Gazyva/Gazyvaro for chronic kidney disease.
Roche Nabs Two FDA Wins in One Day: An All-Oral Breast Cancer Combo and a First-of-Its-Kind Kidney Drug
Get Market Alerts
Weekly insights + SMS alerts
Wilserdly: An All-Oral Combo for a Stubborn Mutation
The FDA approved Wilserdly (giredestrant) plus everolimus for adults with estrogen receptor-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer. Eligible patients need an FDA-authorized test that detects the mutation, and their disease must have recurred or progressed after prior endocrine therapy.
Here is why that matters. Up to 40% of patients with hormone receptor-positive metastatic breast cancer develop ESR1 mutations, and those mutations drive treatment resistance. The new regimen targets two signaling pathways at once and does it entirely with pills, no injections required.
The decision rests on data from the Phase 3 evERA Breast Cancer study published in The New England Journal of Medicine. After prior CDK4/6 inhibitor therapy, Wilserdly plus everolimus reduced the risk of disease progression or death by 62% compared with standard endocrine therapy plus everolimus.
Roche is not stopping there. It also submitted a New Drug Application for Wilserdly as an adjuvant treatment in stage I, II, and III breast cancer based on the Phase 3 lidERA study. The FDA accepted that filing under Priority Review with an action date of November 30, 2026. If it goes through, it would be the first new adjuvant endocrine therapy in over 20 years.
Gazyva: First Through the Door for a Kidney Disease
Separately, the FDA approved Gazyva/Gazyvaro (obinutuzumab) to induce proteinuria remission in adults with primary membranous nephropathy who are at risk of disease progression. The agency had already granted the drug Breakthrough Therapy Designation, and it now becomes the first approved treatment for this autoimmune disease, which can lead to kidney failure.
The numbers from the Phase 3 MAJESTY study are hard to argue with. At 104 weeks, 36.1% of adults achieved complete proteinuria remission versus 5.7% of those taking tacrolimus. Overall remission reached 50% versus 12.9%. Investigators identified no new safety signals.
This is the third FDA approval for Gazyva/Gazyvaro in immune-mediated kidney diseases. And there is more in the pipeline: the FDA expects to decide on its systemic lupus erythematosus application by December 2026, following a positive recommendation from European regulators.
RHHBY Price Action: Roche Holding shares were down 0.70% at $60.52 at the time of publication on Tuesday. The stock is approaching its 52-week high of $61.75, according to market data.
More News

Dow Drops 1.4% as Salesforce Leads Software Wreck Ahead of Anthropic's Mega IPO

NVIDIA's Jensen Huang Crisis Could Rewrite the Rules of the AI Boom

Wall Street Swaps Chips for Chicken: Staples Are Crushing Tech Like It's 2001

David Tepper Dumps 46% of Alphabet and Bets $172M on Oracle's AI Debt Story

Bitcoin Near $64,000 Is an 'Attractive Entry Point,' Grayscale Says After Brutal Two Weeks

Home Depot Hands the Keys to Its CFO as Profit Outlook Gets Trimmed

Fed Warns Leveraged ETFs Could Supercharge Selloffs as South Koreans Bet $3.8B on SOXL

AMD Stock Rises as NVIDIA's Leadership Shakeup Could Hand It a Big AI Opening
Get Market News Alerts
Real-time alerts on price moves, news, and trading opportunities.
Join 20,000+ investors. No spam, ever.
Featured Articles
View all news
Dow Drops 1.4% as Salesforce Leads Software Wreck Ahead of Anthropic's Mega IPO

NVIDIA's Jensen Huang Crisis Could Rewrite the Rules of the AI Boom

Wall Street Swaps Chips for Chicken: Staples Are Crushing Tech Like It's 2001

David Tepper Dumps 46% of Alphabet and Bets $172M on Oracle's AI Debt Story

Bitcoin Near $64,000 Is an 'Attractive Entry Point,' Grayscale Says After Brutal Two Weeks

Home Depot Hands the Keys to Its CFO as Profit Outlook Gets Trimmed

Fed Warns Leveraged ETFs Could Supercharge Selloffs as South Koreans Bet $3.8B on SOXL






